Dr. Rohan Ramakrishna has been awarded two grants for the study of glioma:
• The William Rhodes and Louise Tilzer-Rhodes Center for Glioblastoma at NewYork-Presbyterian awarded Dr. Ramakrishna and his partners, Dr. Howard Fine and Dr. Dan-Avi Landau, a $250,000 seed grant to study the impact of genetic alterations on cellular states in glioma. In this initiative, the investigators will utilize single-cell sequencing techniques pioneered by the Landau lab to characterize the epigenetic encoding of cell state programs in glioma. The project will also reconstruct high-resolution lineage histories of glioma single cells in an effort to measure heritability and estimate plasticity of cell states.
•Nico Corporation has awarded a one-year, $30,000 grant to study how the automated handling of glioma specimens affects the quality of the tissue to be analyzed. In this study, Dr. Ramakrishna is collaborating with Dr. Howard Fine in Neuro-oncology and Dr. Olivier Elemento of the Englander institute of Precision Medicine to study whether automated tissue processing in the operating room affects cell culture results, measures of clonality and heterogeneity, and even tissue immune infiltrates.
Dr. Ramakrishna is Co-Director of the Rhodes Center for Glioblastoma at NewYork-Presbyterian, Director of the Brain Metastasis Program at Weill Cornell Medicine, and Chief of Neurological Surgery at NewYork-Presbyterian Brooklyn Methodist.